Advantages of Skin Stem Cells

Your body and in particular your skin, contains cells that are not yet determined with regard to their future form and may be "programmed" by the surrounding tissue to take on any form. These cells are called adult pluripotent stem cells.

These stem cells have a renewal and repair function and replace defective cells. They are our spare parts store and in the case of injuries assure that healing takes place and the organ or cell structure goes back to carrying out its original function.

Embryonic stem cells, also pluripotent cells that develop in the early embryonic stadium into differentiated cells and organs of the developing human being, are not found in adults any more.

Stem cells from your own skin tissue have several advantages when compared with the stem cells from bone marrow, blood of the umbilical cord or peripheral blood that have been transplanted most frequently up until today.

TICEBA - Advantages of skin stem cells


Advantages Skin Stem Cells

  • The skin contains a higher number of valuable mesenchymal, pluripotent stem cells than blood or bone marrow.
  • These valuable mesenchymal, pluripotent stem cells dispose of a high differentiation potential, which means they have not yet been determined with regard to their future form and may thereby be "programmed" into a multitude of cell types. Therefore, the cells from the skin and the stem cells contained therein obtained by TICEBA have a wider scope of possible fields of application.
  • The valuable mesenchymal, pluripotent stem cells obtained by TICEBA are more easily grown, thereby making a higher number of stem cells available. This might enable a more efficient treatment. However, this differs from one patient to another.
  • The skin as an organ is easily reached. The sampling of a small piece of skin is therefore uncomplicated and almost painless.
  • Sampling may take place without any problem up to a high age.
News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter